TearCare system versus cyclosporine ophthalmic emulsion for the treatment of moderate-to-severe meibomian gland disease associated dry eye disease in the United States: a cost-utility analysis
TearCare is a cost-effective treatment for MGD-related DED, offering both clinical benefits and cost savings over CsA.
Authors
- Nathan Lighthizer
- Roberta Longo (ORCID: https://orcid.org/0000-0002-9379-1627)
- Lorie Mody (ORCID: https://orcid.org/0009-0002-7730-3512)
- Chad Patel
- Thomas Chester
- Patrick M. Riley (ORCID: https://orcid.org/0009-0009-5939-2559)
- Bonnie-Kim Schwertz
Institutions
- Northeastern State University (US)
- Telesage (United States) (US)
- Eye Center (SA)
- Cleveland Eye Clinic (US)
- EyeSight Foundation of Alabama (US)
- Renesas Electronics (United States) (US)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1080/14737167.2025.2537850
- Citations
- 1
- Primary Topic
- Ocular Surface and Contact Lens
- Type
- article
- Field-Weighted Citation Impact
- 1.88